South Korea
· Delayed Price · Currency is KRW J2KBIO Statistics
Total Valuation
J2KBIO has a market cap or net worth of KRW 52.91 billion. The enterprise value is 42.77 billion.
| Market Cap | 52.91B |
| Enterprise Value | 42.77B |
Important Dates
The next estimated earnings date is Friday, March 28, 2025.
| Earnings Date | Mar 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
J2KBIO has 5.71 million shares outstanding. The number of shares has increased by 5.94% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 5.71M |
| Shares Change (YoY) | +5.94% |
| Shares Change (QoQ) | +4.24% |
| Owned by Insiders (%) | 63.48% |
| Owned by Institutions (%) | 6.91% |
| Float | 2.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.43 |
| PB Ratio | 1.72 |
| P/TBV Ratio | 1.74 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.09, with an EV/FCF ratio of -40.63.
| EV / Earnings | -65.17 |
| EV / Sales | 1.23 |
| EV / EBITDA | 7.09 |
| EV / EBIT | 8.01 |
| EV / FCF | -40.63 |
Financial Position
The company has a current ratio of 6.96, with a Debt / Equity ratio of 0.08.
| Current Ratio | 6.96 |
| Quick Ratio | 5.70 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | 0.38 |
| Debt / FCF | -2.19 |
| Interest Coverage | 32.29 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 631.02M |
| Profits Per Employee | -11.93M |
| Employee Count | 52 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 11,655.20 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 39.79 |
| Average Volume (20 Days) | 24,693 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, J2KBIO had revenue of KRW 34.71 billion and -656.35 million in losses. Loss per share was -123.14.
| Revenue | 34.71B |
| Gross Profit | 13.72B |
| Operating Income | 5.34B |
| Pretax Income | 262.97M |
| Net Income | -656.35M |
| EBITDA | 6.03B |
| EBIT | 5.34B |
| Loss Per Share | -123.14 |
Balance Sheet
The company has 12.44 billion in cash and 2.31 billion in debt, giving a net cash position of 10.14 billion or 1,774.24 per share.
| Cash & Cash Equivalents | 12.44B |
| Total Debt | 2.31B |
| Net Cash | 10.14B |
| Net Cash Per Share | 1,774.24 |
| Equity (Book Value) | 30.75B |
| Book Value Per Share | 5,381.90 |
| Working Capital | 16.72B |
Cash Flow
In the last 12 months, operating cash flow was 6.23 billion and capital expenditures -7.29 billion, giving a free cash flow of -1.05 billion.
| Operating Cash Flow | 6.23B |
| Capital Expenditures | -7.29B |
| Free Cash Flow | -1.05B |
| FCF Per Share | -184.25 |
Margins
Gross margin is 39.54%, with operating and profit margins of 15.38% and -1.89%.
| Gross Margin | 39.54% |
| Operating Margin | 15.38% |
| Pretax Margin | 0.76% |
| Profit Margin | -1.89% |
| EBITDA Margin | 17.38% |
| EBIT Margin | 15.38% |
| FCF Margin | n/a |
Dividends & Yields
J2KBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.94% |
| Shareholder Yield | -5.94% |
| Earnings Yield | -1.33% |
| FCF Yield | -1.99% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
J2KBIO has an Altman Z-Score of 17.29.
| Altman Z-Score | 17.29 |
| Piotroski F-Score | n/a |